The Pharmacological Profile of a Novel Highly Potent Bisphosphonate, OX14 (1-Fluoro-2-(Imidazo-[1,2-α]Pyridin-3-yl)-Ethyl-Bisphosphonate).

about

The Pharmacological Profile of a Novel Highly Potent Bisphosphonate, OX14 (1-Fluoro-2-(Imidazo-[1,2-α]Pyridin-3-yl)-Ethyl-Bisphosphonate).

Item

http://www.wikidata.org/entity/Q41689098

description

2017 nî lūn-bûn

@nan

2017年の論文

@ja

2017年論文

@yue

2017年論文

@zh-hant

2017年論文

@zh-hk

2017年論文

@zh-mo

2017年論文

@zh-tw

2017年论文

@wuu

2017年论文

@zh

2017年论文

@zh-cn

name

The Pharmacological Profile of ...... n-3-yl)-Ethyl-Bisphosphonate).

@en

type

Item

label

The Pharmacological Profile of ...... n-3-yl)-Ethyl-Bisphosphonate).

@en

prefLabel

The Pharmacological Profile of ...... n-3-yl)-Ethyl-Bisphosphonate).

@en

P1476

The Pharmacological Profile of ...... in-3-yl)-Ethyl-Bisphosphonate)

@en

P2093

Aaron A Kwaasi

http://www.w3.org/2001/XMLSchema#string

Adam Mazur

http://www.w3.org/2001/XMLSchema#string

Andrew D Chantry

http://www.w3.org/2001/XMLSchema#string

Darren Lath

http://www.w3.org/2001/XMLSchema#string

Frank H Ebetino

http://www.w3.org/2001/XMLSchema#string

Gwyn Jeans

http://www.w3.org/2001/XMLSchema#string

Holly R Evans

http://www.w3.org/2001/XMLSchema#string

James T Triffitt

http://www.w3.org/2001/XMLSchema#string

Julia Paton-Hough

http://www.w3.org/2001/XMLSchema#string

Maria K Tsoumpra

http://www.w3.org/2001/XMLSchema#string

P2860

Diagnosis and management of osteonecrosis of the jaw: a systematic review and international consensus

Intratibial injection of human multiple myeloma cells in NOD/SCID IL-2Rγ(null) mice mimics human myeloma and serves as a valuable tool for the development of anticancer strategies

Tgf-Beta inhibition restores terminal osteoblast differentiation to suppress myeloma growth

Transforming growth factor-beta in osteolytic breast cancer bone metastases.

Adjuvant bisphosphonate treatment in early breast cancer: meta-analyses of individual patient data from randomised trials.

Structure-activity relationships for inhibition of farnesyl diphosphate synthase in vitro and inhibition of bone resorption in vivo by nitrogen-containing bisphosphonates.

Mechanisms of action of bisphosphonates: similarities and differences and their potential influence on clinical efficacy.

Bilateral atypical femoral fractures in a patient with multiple myeloma treated with intravenous bisphosphonate therapy.

Clinical efficacy and treatment persistence of monthly minodronate for osteoporotic patients unsatisfied with, and shifted from, daily or weekly bisphosphonates: the BP-MUSASHI study

Zoledronate Attenuates Accumulation of DNA Damage in Mesenchymal Stem Cells and Protects Their Function.

P304

1860-1869

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1002/JBMR.3138

http://www.w3.org/2001/XMLSchema#string

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P50

James E. Dunford

R G Russell

M A Lawson

P577

2017-04-21T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

28337806

http://www.w3.org/2001/XMLSchema#string

P932

5596338

http://www.w3.org/2001/XMLSchema#string